Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Largest Shareholders Are Individual Investors With 31% Ownership, Private Equity Firms Own 31%

Yahoo FinanceJun 19 19:32

Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series

AccesswireJun 12 22:03

Outlook Therapeutics to Present at the Virtual Investor Pitch Conference

Globe NewswireJun 11 21:05

Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Watch the "What This Means" video hereOutlook CEO, Russ Trenary underscores that LYTENAVA (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commission

AccesswireJun 6 22:30

Buy Rating Justified by Outlook Therapeutics' Advancements and Market Prospects

TipRanksMay 29 08:06

Outlook Gets EU Approval for Lytenava for Wet AMD

Seeking AlphaMay 28 23:50